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ABSTRACT 
Background 
Hyposmia can develop with age and in neurodegenerative conditions, including Parkinson’s 
disease (PD). The University of Pennsylvania Smell Identification Test (UPSIT) is a 40-item 
smell test widely used for assessing hyposmia. However, in a number of situations, such as 
identifying hyposmic individuals in large populations, shorter tests are preferable. 
Methods 
We assessed the ability of shorter UPSIT subsets to detect hyposmia in 891 healthy 
participants from the PREDICT-PD study. Shorter subsets included Versions A and B of the 
4-item Pocket Smell Test (PST) and 12-item Brief Smell Identification Test (BSIT). Using a 
data-driven approach, we evaluated screening performances of 23,231,378 combinations of 
1-7 smell items from the full UPSIT to derive “winning” subsets, and validated findings 
separately in another 191 healthy individuals. We then compared discriminatory UPSIT smells 
between PREDICT-PD participants and 40 PD patients, and assessed the performance of 
“winning” subsets containing discriminatory smells in PD patients. 
Results 
PST Versions A and B achieved sensitivity/specificity of 76.8%/64.9% and 86.6%/45.9% 
respectively, whilst BSIT Versions A and B achieved 83.1%/79.5% and 96.5%/51.8%. From 
the data-driven analysis, 2 “winning” 7-item subsets surpassed the screening performance of 
12-item BSITs (validation sensitivity/specificity of 88.2%/85.4% and 100%/53.5%), whilst a 
“winning” 4-item subset had higher sensitivity than PST-A, -B and even BSIT-A (validation 
sensitivity 91.2%). Interestingly, several discriminatory smells featured within “winning” 
subsets, and demonstrated high screening performances for identifying hyposmic PD patients. 
Conclusion 
Using abbreviated smell tests could provide a cost-effective means of large-scale hyposmia 
screening, allowing more targeted UPSIT administration in general and PD-related settings.  
 
 
 
 
INTRODUCTION 
 
A reduced ability to detect and recognise smells (hyposmia) commonly develops with 
increasing age (1), and can occur in otherwise healthy individuals as a result of head trauma, 
viral diseases including upper respiratory tract infections, sinusitis, or from inhalation of toxic 
fumes (1,2). In addition, hyposmia is increasingly recognised as an early feature of several 
age-related neurodegenerative disorders, including Parkinson’s disease (PD) (2,3). Indeed, 
hyposmia is observed in up to 90% of PD patients (4), and is considered a sensitive non-
motor symptom for discriminating between PD patients and healthy controls (5). The onset of 
hyposmia is associated with an increased risk of being diagnosed with PD (6–8), and can 
predate motor symptoms by years (9,10). The neural substrate behind olfactory dysfunction 
in PD is incompletely understood; however, neuropathological evidence points to the olfactory 
bulb being among the first regions to demonstrate neuronal loss and accumulation of 
intracytoplasmic a-synuclein rich Lewy bodies (11–13), before the pathology involves more 
central regions. Thus, olfactory dysfunction is increasingly recognised as a potential marker 
for the early identification of neurodegenerative processes (14–16).  
 
Several smell tests have been created to screen for olfactory dysfunction, including tests of 
odour adaptation, discrimination, detection, identification, memory, and suprathreshold 
intensity scaling (17). The University of Pennsylvania Smell Identification Test (UPSIT), 
marketed by Sensonics International as the Smell Identification Test, is reported as the most 
commonly-used smell test worldwide (18), and comprises 40 “scratch-and-sniff” 
microencapsulated odorant strips divided across 4 booklets (10 in each). For each strip, 
participants are required to identify the correct smell from a forced choice of 4 possible 
answers. The total number of smells correctly identified out of 40 is then compared with 
normative age- and sex-specific thresholds for olfactory dysfunction (18). Its popularity reflects 
its ability to be self-administered, to differentiate among different levels of less-than-total 
dysfunction, and to detect malingering.  
 
Shorter smell identification tests have also been developed, either as standalone (versions of 
12-item Brief Smell Identification Test (BSIT)) or preliminary tests (versions of 4-item Pocket 
Smell Test (PST)), to guide later administration of the UPSIT to relevant individuals (see 
Supplementary Table 1). A comprehensive list of these and other smell tests developed have 
been reviewed elsewhere (19). Overall, these tests provide utility in the general assessment 
of olfactory dysfunction, and some have shown sensitivity for certain neurodegenerative 
diseases (20,21). However, to date, there are no smell tests which can confirm the aetiology 
of particular cause of olfactory dysfunction. 
 In this study, we examined the screening performance of the current 4-item PSTs and 12-item 
BSITs in a large group of healthy, older individuals from the PREDICT-PD study, and 
assessed the tests’ ability to detect hyposmia according to the full 40-item UPSIT. We then 
sought to identify novel subset(s) of UPSIT items with superior predictive capabilities in the 
same group, and validated the findings in an independent group of individuals from the same 
study. We hypothesised that smells from these “winning” subsets could be used as a more 
accurate and cost-effective pre-screening tool for olfactory dysfunction, and thus assessed 
certain “winning” subsets on their performance in detecting hyposmia in individuals with PD. 
METHODS 
Participant details 
We used data from the PREDICT-PD cohort, a study of 1,323 individuals recruited from the 
general population in the UK between the ages of 60-80. Details of recruitment into the 
PREDICT-PD study have been described elsewhere (22). Of the 1,067 participants from the 
PREDICT-PD cohort who were sent the full 40-item US version of the UPSIT in the baseline 
year of the study, 891 completed the test that year (mean age 67.3 years, SD 4.8, 61.5% 
female). A group of 191 participants who completed the UPSIT test in only Year 3 of the study 
were used for the validation of “winning” smell subsets (mean age 69.8 years, SD 4.7, 61.8% 
female). Figure 1 outlines the workflow of UPSIT data collection from the PREDICT-PD study.  
Insert Figure 1 around here 
 
A separate group of 40 individuals with established PD, who were positive controls for the 
PREDICT-PD study (mean age 63.8, SD 9.6, 25% female) were also sent and returned the 
full 40-item UPSIT. 
 
Assessment of current abbreviated smell tests 
 
Shorter smell tests marketed by Sensonics International include Versions A and B of the 4-
item PST. A test subject is recommended to undergo full UPSIT testing if they cannot correctly 
identify 1 or more smells in either PST version. The original selection of smells in each version 
of the PST was based upon their relevance to diet and nutrition, household, and public safety, 
rather than empirical evidence relating to smell identification (23). Of the abbreviated 
standalone tests for olfactory dysfunction by the same company, the BSIT is a validated, 
cross-cultural 12-item version of the UPSIT (24). Notably, the smells and response alternatives 
in BSIT Versions A and B have shown to possess some discriminatory power for specific 
neurodegenerative diseases according to the studies on which they were based; BSIT-A for 
AD (20), and BSIT-B for PD (21), although they do not confirm a diagnosis of either disease 
(19).  
 
Scores for all 40 UPSIT smells were recorded for each participant. ‘Hyposmia’ was defined as 
being the lowest 15th centile of UPSIT scores according to age and sex (in 5-year bins). This 
method was used over pre-set threshold scores defined within the UPSIT administration 
manual, given that these thresholds were derived from a US population and the current study 
was undertaken in UK participants. Participants with smell scores below the hyposmic 
thresholds included those who were anosmic (i.e. had complete smell loss). Screening 
performance of each abbreviated smell test for hyposmia detection was assessed against the 
corresponding total UPSIT scores for each participant. For the 4-item PST and 12-item B-SIT 
versions, scores of ≤3 and ≤9 respectively were indicative of a positive hyposmia screen. 
Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) 
were calculated for each test. 
 
Data-driven approach to identify novel optimal smell subsets 
 
The discovery phase for novel smell subsets was undertaken using data from the 891 healthy 
participants (discovery cohort) and assessed all 23,231,378 possible combinations of 1-7 
smells from the total of 40 UPSIT smells. For each smell combination, the ability to detect 
hyposmia was assessed against the full UPSIT score, and was defined in terms of sensitivity, 
specificity, PPV and NPV, as well as different score thresholds for defining hyposmia. For 
example, for each of the 18,643,560 combinations of 7 smell subsets from the full set of 40, 
we assessed screening performance based upon hyposmia being defined as participants 
scoring 0/7, ≤1/7, ≤2/7, ≤3/7, ≤4/7, ≤5/7 and ≤6/7. The different thresholds for each 
combination of 7 smell subsets meant we assessed 130,504,920 sets of smell combinations 
and hyposmia thresholds. Combining this with the same approach for 1-6 smell subsets led to 
the assessment of a total 157,222,040 possible screening tests. 
 
A “winning” subset of smells at each hyposmia threshold was selected according to those with 
the highest combined sensitivity and specificity. For example, when considering 5 smell items 
at a threshold of ≤4 to define hyposmia, sensitivity was the number of people who both 
correctly identified ≤4 of the 5 smells and were defined as hyposmic according to the full 
UPSIT, divided by the total number of hyposmic participants according to the full UPSIT. 
Specificity was the number of people who correctly identified all 5 smells in the subset and 
were not hyposmic according to the full UPSIT, divided by all those who were not hyposmic 
as defined by the full UPSIT. These two values were then summed and the combination of 
smells with the highest combined value was deemed to be the “winner” for that specific 
threshold. The same process was repeated for every threshold of hyposmia, for all numbers 
of smell combinations. 
 
Using this method, rather than the area under curve (AUC), allowed us to identify the best 
performing combinations of smells across all possible thresholds, rather than one which 
performed best when averaging across a number of thresholds (as an AUC would). Hence, it 
allowed us to identify threshold-specific optimal smell subsets and enable comparison of 
different hyposmia thresholds.  
 
The screening performance of each “winning” subset was re-assessed in an independent 
group of 191 healthy PREDICT-PD participants (validation cohort). There was no overlap in 
the participants included for selecting the “winning” subsets and the subsequent testing of 
them (Figure 1). Therefore, the results reported are more likely to be generalisable and not 
due to overfitting of the model. 
 
Validation of the novel smell subsets in individuals with PD 
 
We then evaluated smell identification in the context of PD. We compared the proportion of 
smells correctly identified by 40 individuals with PD and the healthy PREDICT-PD participants 
for all 40 UPSIT items. For the top 10 smells with the largest difference in correct identification 
between individuals with PD and healthy controls, we looked at how commonly these featured 
in our “winning” smell subsets from the previous phase of the analysis.  “Winning” smell 
subsets containing at least 2 of the top 10 discriminatory smells were subsequently assessed 
for their screening performance in detecting hyposmia in the same individuals with PD, 
compared to currently available PST and BSIT tests. 
 
 
RESULTS 
 
Based on total UPSIT scores and age- and sex-specific thresholds of PREDICT-PD 
participants, 16.2% females (89/548) and 16.0% males (55/343) from the 891 participants in 
the discovery cohort were classified as having hyposmia. Smoke was the most common 
correctly identified smell (851/891), and Turpentine the least common correctly identified smell 
(328/891). Of the 191 validation cohort participants, 13.6% females (16/118) and 24.7% males 
(18/73) were hyposmic. Amongst the 40 PD participants who were sent and completed the 
UPSIT, 70% females (7/10) and 83.3% males (25/30) were hyposmic, in keeping with the 
known higher prevalence of hyposmia in PD patients compared to healthy participants (3).  
 
PST and BSIT hyposmia screening performance 
Table 1 displays the screening performances of abbreviated smell tests assessed in the 
discovery cohort. Using the recommended cut-off score of ≤3 correctly identified smells to 
denote hyposmia, PST Version A detected hyposmia with sensitivity 76.8%, specificity 64.9%, 
PPV 29.3% and NPV 93.6%. PST Version B had a greater sensitivity 88.6% and NPV 94.8%, 
but lower specificity 45.9% and PPV 23.3%. For the 12-item BSITs, the standard cut-off score 
of ≤9 on BSIT-A detected hyposmia with a sensitivity of 83.1%, specificity 79.5%, PPV 43.5% 
and NPV 96.1%. Comparatively, BSIT-B had greater sensitivity 96.5% and NPV 98.7% than 
BSIT-A, but less specificity 51.8% and PPV 27.5%. We also assessed different score 
thresholds of the BSIT, which are presented in full in Supplementary Tables 2 and 3.  
 
Table 1: Screening performance of PST and B-SIT Versions A and B for hyposmia 
detection in discovery cohort, using recommended cut-off scores for hyposmia.  
Shorter test 
version  
Number 
of smells 
Hyposmia 
score 
Sensitivity  Specificity  PPV NPV 
PST Version A 4 ≤3 76.8% 64.9% 29.3% 93.6% 
PST Version B 4 ≤3 86.6% 45.9% 23.3% 94.8% 
BSIT-A 12 ≤9 83.1% 79.5% 43.5% 96.1% 
BSIT-B 12 ≤9 96.5% 51.8% 27.5% 98.7% 
Abbreviations: PPV = Positive predictive value, NPV= Negative Predictive Value 
 
Identifying optimal smell subsets 
We next assessed all combinations of 1-7 smells from the full set of 40 UPSIT smells in the 
discovery cohort, from which there was a total of 28 “winning” smell combinations. Table 2 
shows a selection of these “winning” smell combinations and the threshold scores for defining 
hyposmia. The sensitivity, specificity, PPV and NPV values shown are from their assessment 
in both discovery and validation cohorts. The complete results from the data-driven analysis 
with all 28 “winning” smell combinations at each threshold are presented in full in 
Supplementary Tables 4 and 5, showing their screening performance in the discovery and 
validation cohorts respectively. 
 
Table 2 reveals that the “winning” smell subsets have different relative strengths in terms of 
sensitivity, specificity, PPV and NPV. In both discovery and validation cohorts, optimised 
combinations of 7 smell items showed superior screening performance to the 12-item BSITs. 
7 smells using a cut-off of 4 for hyposmia surpassed the sensitivity/specificity of BSIT-A 
(88.2/85.4 vs 83.1/79.5) and another 7 smells with a hyposmia cut-off of 5 surpassed that of 
the more sensitive BSIT-B (100/53.5 vs 96.5/51.8). Using as few as 6 smell items produced 
comparable screening performance to the 12-item BSIT (sensitivity/specificity for 6 smells with 
a cut-off of 3: 85.3/78.3 vs 83.1/79.5 for BSIT-A). Following acquisition of these results, further 
analysis of smell combinations using >7 UPSIT items was deemed unnecessary and was not 
pursued. 
 
For the purpose of designing a short pre-screening smell test, which would best identify 
individuals who require further smell testing, it was important to maximise sensitivity and NPV 
in order to minimise the number of impaired individuals excluded from further testing. In this 
regard, a 4-item subset (Menthol, Clove, Gingerbread, Orange) with a cut-off of 3 or less 
produced higher sensitivity and NPV scores in both discovery and validation cohorts when 
compared with both current 4-item PST tests (see Table 1, Supplementary Table 4 and 
Table 2).  
Table 2: Screening performance of selected “winning” smell subsets from discovery cohort and re-assessment in validation cohort  
No. of 
smells 
Hyposmia 
cut-off 
score 
Smells “winning” in 
discovery cohort 
Sens. in 
discovery 
cohort 
Spec. in 
discovery 
cohort  
PPV in 
discovery 
cohort 
NPV in 
discovery 
cohort 
Sens. in 
validation 
cohort 
Spec. in 
validation 
cohort  
PPV in 
validation 
cohort 
NPV in 
validation 
cohort 
1 0 Pizza 69.7 66.1 28.0 92.0 82.4 53.5 27.7 93.3 
2 ≤1 Clove, Coconut 62.0 88.7 50.9 92.5 61.8 82.8 43.8 90.9 
3 ≤1 Pizza, Clove, Root beer 72.5 79.3 39.9 93.8 70.6 80.9 44.4 92.7 
4 ≤2 Cherry, Clove, Coconut, 
Root beer 
72.5 87.2 51.8 94.4 61.8 88.5 53.8 91.4 
4 ≤3 Menthol, Clove, 
Gingerbread, Orange 
78.9 82.8 46.5 95.4 91.2 35.0 23.3 94.8 
5 ≤2 Pizza, Clove, Fruit Punch, 
Chocolate, Root beer 
71.8 88.4 54.0 94.3 73.5 84.1 50.0 93.6 
5 ≤4 Menthol, Clove, Onion, 
Gingerbread, Orange 
83.1 80.4 44.5 96.2 94.1 33.8 23.5 96.4 
6 ≤3 Pizza, Clove, Fruit Punch, 
Liquorice, Lime, Pine 
83.8 82.6 47.8 96.4 85.3 78.3 46.0 96.1 
6 ≤4 Menthol, Cherry, Clove, 
Gingerbread, Root beer, 
Orange 
84.5 83.8 49.8 96.6 88.2 65.6 35.7 96.3 
7 ≤4 Cherry, Mint, Clove, Fruit 
Punch, Gingerbread, Root 
beer, Pine 
82.4 87.7 56.0 96.3 88.2 85.4 56.6 97.1 
7 ≤5 Pizza, Menthol, Cherry, 
Clove, Gingerbread, 
Orange, Pine 
87.3 83.0 49.4 97.2 100.0 53.5 31.8 100.0 
Abbreviations: Sens. = Sensitivity, Spec. = Specificity, PPV =Positive Predictive Value, NPV = Negative Predictive Value 
 
Comparison of smell identification between PD and healthy participants  
The results from a comparison of correctly identified UPSIT smell items in the 40 patients with 
PD and the 891 healthy PREDICT-PD participants are shown in Figure 2.  
 
Insert Figure 2 here 
 
The most discriminating smells (i.e. those with the largest differences in correct identification 
between PD patients and PREDICT-PD controls) included Menthol, Orange and Coconut, 
whilst the least discriminating smells included Turpentine, Grape and Grass. Interestingly, 
several of the most discriminating smells frequently featured within the “winning” UPSIT 
combinations chosen for hyposmia detection in healthy individuals from the data-driven 
analysis (Supplementary Tables 4 and 5). 
 
Based on these findings, we assessed the screening performance of “winning” smell subsets 
containing at least 2 of the top 10 discriminatory smells in accurately detecting hyposmia (by 
UPSIT) in the 40 PD patients within this study, compared to the performance of current PST 
and BSIT versions (see Table 3). Improved screening performance was observed in “winning” 
smell subsets that contained discriminating smells, with subsets containing ≥4 discriminating 
smells all having 100% sensitivity for detecting hyposmic PD patients. This included the more 
‘PD-specific’ BSIT-B, which contained 5/10 top discriminatory smells. Significantly, the 4-item 
combination of Menthol, Clove, Gingerbread and Orange used in 4 and 5-item subsets had 
the highest performance score for both sensitivity and specificity (100% and 87.5%) than all 
other smell combinations, surpassing the performance of both 12-item BSITs. In addition, use 
of the 2-item subset of Clove and Coconut had a higher/equal sensitivity to 4-item PST-B and 
PST-A respectively. However, in some smell subsets, higher numbers of discriminating smells 
appeared to decrease specificity; for example, the specificity was reduced from 25% to 12.5% 
in the 4-item combination of Cherry, Clove, Coconut and Root beer, compared to the 2-item 
combination of Clove and Coconut. 
 
 
 
 
 
 
 
Table 3: Screening performance for detecting hyposmia in PD patients using “winning” 
smell subsets which contain at least 2 of the 10 most discriminating smells, compared 
with current abbreviated smell tests  
Smell subsets are ordered according to their respective sensitivities then by specificity. The 
most discriminating smells are highlighted in bold. 
Total 
no. of 
smells 
No. of 
discriminatory 
smells   
Hyposmia 
cut-off 
score 
Abbreviated smell test  Sensitivity  Specificity 
 
4 4 ≤3 Menthol, Clove, 
Gingerbread, Orange 
100% 87.5% 
5 4 ≤4 Menthol, Clove, 
Gingerbread, Orange, 
Onion 
100% 87.5% 
12 5 ≤9 BSIT-B (includes, Clove, 
Coconut, Lemon, 
Wintergreen, Banana) 
100% 62.5% 
7 5 ≤5 Menthol, Cherry, Clove, 
Gingerbread, Orange, 
Pine, Pizza 
100% 37.5% 
6 5 ≤4 Menthol, Cherry, Clove, 
Gingerbread, Orange, 
Root beer 
100% 12.5% 
7 2 ≤6 Menthol, Clove, Leather, 
Lilac, Watermelon, 
Smoke, Rose 
96.9% 37.5% 
6 3 ≤5 Menthol, Clove, 
Gingerbread, Lilac, 
Watermelon, Smoke 
96.9% 25% 
3 3 ≤2 Menthol, Clove, Coconut 96.9% 25% 
5 4 ≤3 Menthol, Cherry, Clove, 
Coconut, Root beer 
96.9% 12.5% 
7 3 ≤4 Cherry, Clove, 
Gingerbread, Fruit Punch, 
Root beer, Pine, Mint 
96.9% 12.5% 
12 2 ≤9 BSIT-A (includes Lemon, 
Banana) 
90.6% 25% 
4 0 ≤3 PST-A (none) 81.3% 37.5% 
2 2 ≤1 Clove, Coconut 81.3% 25% 
4 3 ≤2 Cherry, Clove, Coconut, 
Root beer 
81.3% 12.5% 
4 0 ≤3 PST-B (none) 75% 25% 
DISCUSSION 
 
In the first part of this study, we assessed the screening performance of abbreviated UPSIT 
smell subsets for their ability to detect hyposmia within a large UK-based population of healthy 
individuals in the PREDICT-PD study. On assessment of the current commercially available 
BSIT and PST smell tests (Versions A and B), the 12-item BSITs had an expected greater 
screening performance for detecting hyposmia compared with either 4-item PST. This reflects 
the BSITs’ ability to act as standalone tests for hyposmia, whereas PSTs are intended as a 
pre-screen to target subsequent administration of full UPSIT testing. However, our results 
highlighted differences in the sensitivity and specificity of each 4-item PST, suggesting that 
the accuracy with which they can detect hyposmia varies depending on the version 
administered, which should be taken into consideration with future use.  
 
In our data-driven analysis, we identified novel UPSIT subsets of just 7 smell items that had 
superior screening performance compared to the 12-item BSITs for detecting hyposmia in 
healthy PREDICT-PD individuals. Importantly, these “winning” smell subsets identified in the 
discovery phase appeared to retain their overall screening performance with independent 
testing in the validation phase. Using as few as 6 smell items could offer comparable screening 
performance to the BSIT. Given that these combinations are half the length of the current 
BSIT, expansion of their use could offer obvious benefits in terms of time and expense when 
undertaking large-scale studies, or for use in routine clinical settings.  
 
We also identified a subset of 4 smells (Menthol, Clove, Gingerbread, Orange) which had a 
high screening performance in the discovery cohort, and identified a greater proportion of 
individuals with hyposmia than either Version A or B of the 4-item PST when reassessed in 
the independent validation group. While the above 7 and 6 item tests may be suitable for 
standalone testing, this optimised 4-item subset may be an ideal pre-screen test, before 
selective use of the UPSIT for assessing olfactory dysfunction in the general population. 
Nevertheless, it is still important to remember that whilst shorter test versions may provide an 
effective method for hyposmia screening, they do not have the added benefits that longer tests 
offer in being able to distinguish between levels of less-than-total olfactory dysfunction or for 
identifying malingering, hence should not be seen as a substitute for more extensive forms of 
smell testing. 
 
In the context of assessing hyposmia in PD, studies have consistently demonstrated that PD 
patients have lower total UPSIT scores compared with healthy controls (25,26), which was 
borne out in our results. In the second part of this study, we attempted to investigate whether 
any of our “winning” shorter smell subsets also had value in assessing hyposmia in patients 
with PD. Specifically, we assessed differences in correct smell identification responses 
between the 40 PD and 891 healthy PREDICT-PD individuals of this study to investigate for 
discriminatory smells. Interestingly, Menthol, Clove, Gingerbread and Orange featured 
amongst the top 10 discriminatory smells, and when included within 4 and 5 item subsets 
correctly identified hyposmia in all of the 32 hyposmic patients with PD, as well as correctly 
classified 7 of the 8 normosmic patients with PD (sensitivity/specificity 100% and 87.5%), 
surpassing the screening performance of both 12-item BSITs. Further investigation into the 
utility of these smell subsets for hyposmia detection in larger PD cohorts would be of benefit. 
However, while the present study demonstrates the ability of certain smell subsets to detect 
hyposmia in individuals with PD (as well as the healthy population), it does not offer 
confirmatory evidence of there being a PD-specific patterns of olfactory dysfunction. Formal 
comparison with hyposmia due to other causes would be required to make claims as to such 
disease-specific detection.  
   
Indeed, there has been extensive debate as to whether specific smells are lost preferentially 
over the course of PD. Some work suggests specific smells can differentiate people with and 
without PD (27–29), however there is significant variability between which smells are 
implicated, whilst others have found no evidence of PD-specific smell loss (25,30). By 
example, a recent study attempting to devise novel UPSIT subsets specific for the detection 
of PD found subsets with good screening performance in discovery analyses, but failed to 
retain this performance when reassessed in independent groups (19). Overall, these variable 
findings may be due to several confounding factors, including the choice of smell test, 
alternative smell (‘distractor’) options, study populations and cultural differences.  
 
Alternative methods to increase the screening performance of smell tests for identifying 
individuals at risk of PD have also been investigated. These methods include combination of 
smell scores with other early, non-motor PD manifestations, such as constipation, sleep 
disturbances and depression (16,31). Moreover, a recent study identified a PD-specific 
response pattern of 12 incorrect UPSIT question/response pairs in PD participants compared 
to healthy controls (32), which appeared more valuable for PD diagnosis than total mean 
UPSIT score. Assessing for this sort of disease-specific olfactory loss was beyond the scope 
of the present study, but would certainly merit further work in the future. Additional adaptations 
in the design of future smell tests could also include the use of confidence ratings into each 
answer panel, ranking from 1 (least confident) to 4 (very confident), to provide a greater yield 
of information over individuals’ identification of specific smells without lengthening the test.  
 
A key strength of the present study is its size. To the best of our knowledge, this is the largest 
assessment of screening performance of abbreviated versions of smell identification tests in 
comparison to the full 40-item UPSIT. However, there are certain limitations. Firstly, given that 
the assessment of all of abbreviated smell tests was based upon comparison with participants’ 
total UPSIT score, we are assuming that it still remains an accurate and sensitive tool for 
detecting hyposmia in the general healthy population as validated by Doty et al (33). The three 
‘distractor’ options used in both PST versions may also differ from those for the same smells 
in the full UPSIT test (see Supplementary Table 6). These different distractors could have 
influenced participants’ ability to identify the smells to some degree, but the impact on overall 
screening performance assessed is likely to be relatively small given that the target smells are 
the same. In the same way, given that our data-driven analysis of multiple UPSIT smell 
combinations was based on existing UPSIT data from participants, we acknowledge the 
potential influence of distractor options for each smell on the correct identification, and thus 
the ranking of “winning” smell subsets. 
 
Another limitation is that the current study used the original US version of the UPSIT, but in a 
UK population, which might have lowered overall performance due to reduced familiarity with 
some of the smells. For example, Wintergreen is likely to be more familiar to an American 
population than in the UK. Indeed, a previous UK based study using the US UPSIT found 
certain smells to have low identification rates (34). The smells with lowest cross-cultural 
detection included Root beer (52.3%), Lime (56.8%), Dill pickle (61.4%) and Turpentine 
(65.9%) (34), which was borne out in our own data as some of the poorest identified smells in 
healthy participants, as well as the worst discriminating smells between PD patients and 
healthy participants. Of note, Turpentine and Grape were the only two smells within our study 
that had a higher correct detection by PD patients than healthy participants. In light of these 
issues, “winning” subsets which only include smells present in the UK UPSIT version are 
provided in Supplementary Table 7.  
 
Finally, while the current study identified individuals as ‘hyposmic’ based on specific age and 
sex threshold cut offs within the PREDICT-PD population, the data-driven approach did not 
include age or sex in their parameters for assessment of “winning” USPIT smell subsets at 
each threshold-cut off. Given the established influence of age and sex on olfaction (2,35), it is 
possible that their inclusion in the analysis could lead to further improvement in the screening 
performance of abbreviated subsets, and this will be evaluated in future work. 
 
 
 
CONCLUSION 
 
Accurate assessment of olfactory dysfunction may assist in the early detection of certain 
neurodegenerative diseases such as PD. Using a data-driven approach, our study identified 
several “winning” 1-7 UPSIT smell subsets with high screening performance for hyposmia 
detection in 891 healthy participants of the PREDICT-PD study. Of note, 7-item subsets 
demonstrated superior screening performance to current 12-item BSIT versions, which was 
retained on re-assessment within an independent cohort. Our study also found that “winning” 
subsets containing smells which had large differences in correct identification rates between 
individuals with and without PD also produced high screening performances when assessing 
for hyposmia in individuals with PD, including Menthol, Clove, Gingerbread and Orange. 
Notably, several 3-, 4- and 5-item subsets incorporating some of the top 10 discriminatory 
identified more PD patients with hyposmia than current PST and even BSIT-A test versions. 
Significant cost and efficiency savings may be gained by using these smell combinations 
within an abbreviated smell test to target more focussed administration of the full UPSIT for 
wider scale clinical and research purposes, in both general and PD-related settings.  
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FIGURE CAPTIONS 
 
Fig.1 Schematic workflow of PREDICT-PD participation in Year 0 and Year 3 UPSIT smell 
testing and useable data for ‘discovery’ and ‘validation’ cohort smell test analysis 
 
Fig.2 Identification rates of the 40 individual smells in the full UPSIT in 40 PD participants 
(green) and 891 healthy PREDICT-PD controls (red).  
 
(underneath Figure 2: Smells ordered by those with the greatest difference in correct smell 
identification by PD participants’ versus healthy controls on the left to ever decreasing values 
on the right.) 
 
